vs
LivaNova PLC（LIVN）与迈心诺（MASI）财务数据对比。点击上方公司名可切换其他公司
迈心诺的季度营收约是LivaNova PLC的1.0倍（$371.5M vs $360.9M）。LivaNova PLC净利率更高（8.6% vs -27.0%，领先35.6%）。LivaNova PLC同比增速更快（12.1% vs -26.4%）。迈心诺自由现金流更多（$50.9M vs $50.2M）。过去两年LivaNova PLC的营收复合增速更高（10.6% vs -17.7%）
LivaNova PLC是一家深耕医疗设备领域的企业，总部位于英国，核心业务为研发心脏外科及神经调控类医疗设备。该公司由美国Cyberonics公司与意大利Sorin公司于2015年以27亿美元对价合并成立，目前在纳斯达克挂牌交易，股票代码为LIVN。
迈心诺（Masimo Corporation）是总部位于美国加利福尼亚州尔湾的健康科技及消费电子企业，核心产品包括面向医院及家用场景的患者监护设备、无创传感器及配套软件平台，同时也布局了消费级音频和可穿戴设备赛道。
LIVN vs MASI — 直观对比
营收规模更大
MASI
是对方的1.0倍
$360.9M
营收增速更快
LIVN
高出38.5%
-26.4%
净利率更高
LIVN
高出35.6%
-27.0%
自由现金流更多
MASI
多$736.0K
$50.2M
两年增速更快
LIVN
近两年复合增速
-17.7%
损益表 — Q4 2025 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $360.9M | $371.5M |
| 净利润 | $30.9M | $-100.4M |
| 毛利率 | 65.2% | 62.1% |
| 营业利润率 | 11.8% | 22.5% |
| 净利率 | 8.6% | -27.0% |
| 营收同比 | 12.1% | -26.4% |
| 净利润同比 | -44.7% | -1124.5% |
| 每股收益（稀释后） | $0.57 | $-1.84 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LIVNMASI
| Q4 25 | $360.9M | — | ||
| Q3 25 | $357.8M | $371.5M | ||
| Q2 25 | $352.5M | $370.9M | ||
| Q1 25 | $316.9M | $372.0M | ||
| Q4 24 | $321.8M | $600.7M | ||
| Q3 24 | $318.1M | $504.6M | ||
| Q2 24 | $318.6M | $496.3M | ||
| Q1 24 | $294.9M | $492.8M |
净利润LIVNMASI
| Q4 25 | $30.9M | — | ||
| Q3 25 | $26.8M | $-100.4M | ||
| Q2 25 | $27.2M | $51.3M | ||
| Q1 25 | $-327.3M | $-170.7M | ||
| Q4 24 | $55.9M | $-349.6M | ||
| Q3 24 | $33.0M | $9.8M | ||
| Q2 24 | $16.3M | $16.0M | ||
| Q1 24 | $-41.9M | $18.9M |
毛利率LIVNMASI
| Q4 25 | 65.2% | — | ||
| Q3 25 | 68.4% | 62.1% | ||
| Q2 25 | 67.8% | 62.9% | ||
| Q1 25 | 69.7% | 62.9% | ||
| Q4 24 | 68.2% | 40.7% | ||
| Q3 24 | 70.8% | 52.2% | ||
| Q2 24 | 68.7% | 51.3% | ||
| Q1 24 | 70.3% | 49.0% |
营业利润率LIVNMASI
| Q4 25 | 11.8% | — | ||
| Q3 25 | 15.1% | 22.5% | ||
| Q2 25 | 15.4% | 17.4% | ||
| Q1 25 | 15.3% | 21.0% | ||
| Q4 24 | 11.5% | -59.8% | ||
| Q3 24 | 11.2% | 6.0% | ||
| Q2 24 | 12.6% | 5.7% | ||
| Q1 24 | 5.5% | 6.9% |
净利率LIVNMASI
| Q4 25 | 8.6% | — | ||
| Q3 25 | 7.5% | -27.0% | ||
| Q2 25 | 7.7% | 13.8% | ||
| Q1 25 | -103.3% | -45.9% | ||
| Q4 24 | 17.4% | -58.2% | ||
| Q3 24 | 10.4% | 1.9% | ||
| Q2 24 | 5.1% | 3.2% | ||
| Q1 24 | -14.2% | 3.8% |
每股收益（稀释后）LIVNMASI
| Q4 25 | $0.57 | — | ||
| Q3 25 | $0.49 | $-1.84 | ||
| Q2 25 | $0.50 | $0.94 | ||
| Q1 25 | $-6.01 | $-3.12 | ||
| Q4 24 | $1.04 | $-6.54 | ||
| Q3 24 | $0.60 | $0.18 | ||
| Q2 24 | $0.30 | $0.29 | ||
| Q1 24 | $-0.78 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $635.6M | $312.3M |
| 总债务越低越好 | $376.1M | $559.1M |
| 股东权益账面价值 | $1.2B | $810.0M |
| 总资产 | $2.6B | $1.8B |
| 负债/权益比越低杠杆越低 | 0.31× | 0.69× |
8季度趋势，按日历期对齐
现金及短期投资LIVNMASI
| Q4 25 | $635.6M | — | ||
| Q3 25 | $646.1M | $312.3M | ||
| Q2 25 | $593.6M | $149.6M | ||
| Q1 25 | $738.4M | $130.8M | ||
| Q4 24 | $428.9M | $177.6M | ||
| Q3 24 | $346.4M | $158.5M | ||
| Q2 24 | $329.2M | $129.6M | ||
| Q1 24 | $309.2M | $157.6M |
总债务LIVNMASI
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | $559.1M | ||
| Q2 25 | $430.6M | $613.7M | ||
| Q1 25 | $628.2M | $651.0M | ||
| Q4 24 | $627.0M | $765.2M | ||
| Q3 24 | $625.5M | $772.6M | ||
| Q2 24 | $624.5M | $781.6M | ||
| Q1 24 | $623.8M | $876.0M |
股东权益LIVNMASI
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | $810.0M | ||
| Q2 25 | $1.1B | $1.0B | ||
| Q1 25 | $1.0B | $946.4M | ||
| Q4 24 | $1.3B | $1.1B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $1.2B | $1.4B | ||
| Q1 24 | $1.2B | $1.4B |
总资产LIVNMASI
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | $1.8B | ||
| Q2 25 | $2.5B | $2.4B | ||
| Q1 25 | $2.6B | $2.3B | ||
| Q4 24 | $2.5B | $2.6B | ||
| Q3 24 | $2.5B | $3.1B | ||
| Q2 24 | $2.5B | $2.9B | ||
| Q1 24 | $2.5B | $3.0B |
负债/权益比LIVNMASI
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | 0.69× | ||
| Q2 25 | 0.38× | 0.59× | ||
| Q1 25 | 0.61× | 0.69× | ||
| Q4 24 | 0.47× | 0.73× | ||
| Q3 24 | 0.48× | 0.53× | ||
| Q2 24 | 0.50× | 0.57× | ||
| Q1 24 | 0.51× | 0.64× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $82.4M | $56.8M |
| 自由现金流经营现金流 - 资本支出 | $50.2M | $50.9M |
| 自由现金流率自由现金流/营收 | 13.9% | 13.7% |
| 资本支出强度资本支出/营收 | 8.9% | 1.6% |
| 现金转化率经营现金流/净利润 | 2.67× | — |
| 过去12个月自由现金流最近4个季度 | $173.3M | $191.0M |
8季度趋势，按日历期对齐
经营现金流LIVNMASI
| Q4 25 | $82.4M | — | ||
| Q3 25 | $85.1M | $56.8M | ||
| Q2 25 | $62.9M | $69.4M | ||
| Q1 25 | $24.0M | $31.1M | ||
| Q4 24 | $78.7M | $50.5M | ||
| Q3 24 | $51.0M | $25.6M | ||
| Q2 24 | $43.4M | $74.5M | ||
| Q1 24 | $10.0M | $45.8M |
自由现金流LIVNMASI
| Q4 25 | $50.2M | — | ||
| Q3 25 | $62.2M | $50.9M | ||
| Q2 25 | $47.8M | $65.6M | ||
| Q1 25 | $13.2M | $28.5M | ||
| Q4 24 | $68.3M | $46.0M | ||
| Q3 24 | $32.8M | $16.9M | ||
| Q2 24 | $31.2M | $66.9M | ||
| Q1 24 | $3.6M | $37.6M |
自由现金流率LIVNMASI
| Q4 25 | 13.9% | — | ||
| Q3 25 | 17.4% | 13.7% | ||
| Q2 25 | 13.6% | 17.7% | ||
| Q1 25 | 4.2% | 7.7% | ||
| Q4 24 | 21.2% | 7.7% | ||
| Q3 24 | 10.3% | 3.3% | ||
| Q2 24 | 9.8% | 13.5% | ||
| Q1 24 | 1.2% | 7.6% |
资本支出强度LIVNMASI
| Q4 25 | 8.9% | — | ||
| Q3 25 | 6.4% | 1.6% | ||
| Q2 25 | 4.3% | 1.0% | ||
| Q1 25 | 3.4% | 0.7% | ||
| Q4 24 | 3.2% | 0.7% | ||
| Q3 24 | 5.7% | 1.7% | ||
| Q2 24 | 3.8% | 1.5% | ||
| Q1 24 | 2.2% | 1.7% |
现金转化率LIVNMASI
| Q4 25 | 2.67× | — | ||
| Q3 25 | 3.18× | — | ||
| Q2 25 | 2.32× | 1.35× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 1.55× | 2.61× | ||
| Q2 24 | 2.65× | 4.66× | ||
| Q1 24 | — | 2.42× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
MASI
暂无分部数据
